Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LV-SMENP Vaccine
- Development stage
- Unknown
- Lead developer
- Shenzhen Geno-Immune Medical Institute
- Modality
- Cell Therapies, Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
LV-SMENP Vaccine is an investigational cell-based gene therapy vaccine developed for the prophylaxis of COVID-19. It consists of dendritic cells (DCs) that are genetically modified using a lentiviral vector to express synthetic minigenes derived from selected domains of SARS-CoV-2 viral proteins, along with immune modulatory genes. The vaccine is designed to activate antigen-specific cytotoxic T lymphocytes (CTLs), thereby inducing a targeted cellular immune response against SARS-CoV-2. Administration involves both the modified dendritic cells and activated CTLs. The developer is Shenzhen Geno-Immune Medical Institute, and as of 2020–2021, it has been in early-phase clinical trials for COVID-19 prevention[1][2][3][4][5][7][8].
- Other names
- Covid-19 Synthetic Minigene VaccineCovid19 Synthetic Minigene VaccineCovid 19 Synthetic Minigene VaccineLentiviral Minigene Vaccine
02
Targets
TCR (T cell antigen receptor complex)
Beyond the preview
Go deeper on LV-SMENP Vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LV-SMENP Vaccine.